Assembly Biosciences (ASMB) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.20

Estimate

-$0.52

Surprise

+61.9%

Revenue (period 2026-06-30)

$13.4M

Score today

6.2/10

Revenue source: xbrl.

Assembly Biosciences (ASMB) reported a narrower loss than forecast — diluted EPS of -$0.20 against the -$0.52 estimate (a 61.9% beat on a still-unprofitable quarter).

• Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate — benzinga, 2026-08-13

TrendMatrix currently rates ASMB Sell at 6.2/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +61.9% surprise compares with a +114.9% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$36.78

Price target

$45.24

Stop

$34.04

Upside to target

+23.0%

Reward-to-risk

1.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$745.2M

P/E (fwd)

-14.1

P/E (ttm)

29.3

52-week range

$20.23–$39.71

Off 52-week high

7.4%

RSI (14)

78

Volume vs avg

0.51×

Score today

6.2/10